# SAFEGUARD: Pleiotropic Effects of Incretin Based Therapies

> **NCT01744236** · PHASE4 · COMPLETED · sponsor: **Amsterdam UMC, location VUmc** · enrollment: 70 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Liraglutide
- **DRUG:** Sitagliptin
- **DRUG:** Exenatide
- **DRUG:** Liraglutide placebo
- **DRUG:** Sitagliptin placebo
- **DRUG:** Exenatide placebo
- **DRUG:** L-NMMA

## Key facts

- **NCT ID:** NCT01744236
- **Lead sponsor:** Amsterdam UMC, location VUmc
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04
- **Primary completion:** 2015-08
- **Final completion:** 2015-08
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2015-12-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01744236

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01744236, "SAFEGUARD: Pleiotropic Effects of Incretin Based Therapies". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01744236. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*